- Home
- ACAD vs CRC Comparison
ACAD vs CRC Comparison
Compare ACAD & CRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CRC
- Stock Information
- Founded
- ACAD 1993
- CRC 2014
- Country
- ACAD United States
- CRC United States
- Employees
- ACAD N/A
- CRC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CRC Oil & Gas Production
- Sector
- ACAD Health Care
- CRC Energy
- Exchange
- ACAD Nasdaq
- CRC Nasdaq
- Market Cap
- ACAD 3.8B
- CRC 4.2B
- IPO Year
- ACAD 2004
- CRC N/A
- Fundamental
- Price
- ACAD $20.98
- CRC $48.01
- Analyst Decision
- ACAD Buy
- CRC Strong Buy
- Analyst Count
- ACAD 18
- CRC 11
- Target Price
- ACAD $27.71
- CRC $61.27
- AVG Volume (30 Days)
- ACAD 2.0M
- CRC 929.2K
- Earning Date
- ACAD 08-05-2025
- CRC 08-05-2025
- Dividend Yield
- ACAD N/A
- CRC 3.24%
- EPS Growth
- ACAD N/A
- CRC 61.94
- EPS
- ACAD 1.37
- CRC 5.76
- Revenue
- ACAD $996,283,000.00
- CRC $3,312,000,000.00
- Revenue This Year
- ACAD $13.39
- CRC $12.21
- Revenue Next Year
- ACAD $10.59
- CRC N/A
- P/E Ratio
- ACAD $15.33
- CRC $8.31
- Revenue Growth
- ACAD 22.42
- CRC 43.01
- 52 Week Low
- ACAD $13.40
- CRC $30.97
- 52 Week High
- ACAD $25.23
- CRC $60.41
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- CRC 61.85
- Support Level
- ACAD $20.75
- CRC $46.96
- Resistance Level
- ACAD $23.09
- CRC $48.30
- Average True Range (ATR)
- ACAD 0.78
- CRC 1.14
- MACD
- ACAD -0.20
- CRC 0.00
- Stochastic Oscillator
- ACAD 9.83
- CRC 79.62
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CRC California Resources Corporation
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.